Vectibix recommended for colorectal cancer in Japan
This article was originally published in Scrip
Takeda has received an approval recommendation in Japan for its EGFR-targeted human monoclonal antibody, Vectibix (panitumumab), for the treatment of colorectal cancer.
You may also be interested in...
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.